Freenome · Series D · $1.1B+ raised
📍 Remote
Listed September 7, 2026
Freenome is developing blood-based tests that use machine learning and multiomics to detect cancer earlier, when treatment can be most effective. Its work combines large clinical datasets, computational biology, diagnostics, and regulated healthcare product development.
Sign up free to see the apply link and more roles like this.